<DOC>
	<DOCNO>NCT00825201</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell stop divide . Giving paclitaxel albumin-stabilized nanoparticle formulation directly abdomen may kill tumor cell . PURPOSE : This phase I trial study side effect best dose intraperitoneal paclitaxel albumin-stabilized nanoparticle formulation treat patient advanced cancer peritoneal cavity .</brief_summary>
	<brief_title>Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation Treating Patients With Advanced Cancer Peritoneal Cavity</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximally tolerate dose ( MTD ) nab-paclitaxel single agent administer intraperitoneally via intraperitoneal catheter . SECONDARY OBJECTIVES : I . To evaluate pharmacokinetics nab-paclitaxel ( Abraxane ) plasma peritoneum administer directly peritoneal cavity . II . To determine potential pharmacokinetic advantage ( favorable ratio nab-paclitaxel ( Abraxane ) concentration peritoneal cavity vs. plasma ) nab-paclitaxel administer intraperitoneally . III . To determine progression peripheral neuropathy patient treat intraperitoneal chemotherapy study pre-treatment sequential evaluation Neuropathic Pain Syndrome Inventory Serial Nerve Conduction Studies . OUTLINE : This dose-escalation study . Patients receive paclitaxel albumin-stabilized nanoparticle formulation give intraperitoneally ( IP ) day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients must histological confirmed advanced cancer primarily confine peritoneal cavity progress previous chemotherapeutic regimen , `` standard '' chemotherapeutic regimen exist Prior taxane exposure allow ; prior IP chemotherapy allow , complicate peritoneal adhesion ; patient ovarian cancer residual disease secondlook laparotomy follow secondary debulking also eligible ; patient must 46 week surgery must recover surgery prior initiate IP chemotherapy Eastern Cooperative Oncology Group ( ECOG ) less equal 2 Life expectancy great 3 month Absolute neutrophil count &gt; 1,500/mcL Platelets &gt; 100,000/mcL Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamic pyruvic transaminase [ SGPT ] ) &lt; 2.5 x institutional upper limit normal Creatinine within normal institutional limit creatinine clearance &gt; 60 mL/min/1.73 m^2 patient creatinine level institutional normal Documentation measurable disease ( baseline measurement take 4 week study entry , present appropriate ) ; presence measurable disease , per se , prerequisite entry onto study Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier ; limit number prior line chemotherapy Patients may receive investigational agent Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event History allergic reaction attribute compound similar chemical biologic composition nabpaclitaxel Patients ongoing abdominal infection bowel obstruction Patients know peritoneal adhesion preclude placement intraperitoneal catheter opinion surgeon place intraperitoneal catheter Preexisting grade &gt; = 2 sensory neuropathy Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated nabpaclitaxel Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy `` Massive Ascites '' require therapeutic paracentesis , cause ineligibility , per se , evaluate individual basis ; investigator question regard assess ascites ask speak Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>peritoneal carcinomatosis</keyword>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>